Tazemetostat
As of the edition of 20 October 2026, Tazemetostat is a small molecule: marketed, first approved in 2020 (US); acts on EZH2; US protection ends in 2034.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Tazverik
- First approved
- 23 January 2020 (US)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- Eisai; 2 holders in all
- Registered trials
- 55, 15 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Urinary and reproductive; Pregnancy and women's health; Lungs and airways
US protection
US protection ends in 2034.
The last listed US drug-substance patent ends in 2034. The application that gives this date is held by Ipsen.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product11 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 11 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Tazemetostat.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EZH2 | Histone-lysine N-methyltransferase EZH2 | Q15910 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 0 | 1 | 0 |
| Phase 1 | 18 | 6 | 5 | 7 |
| Phase 2 | 33 | 9 | 15 | 8 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 55 |